Tools for Profiling Inhibitors of Full-Length LRRK2
20 October 2016
Parkinson's Disease (PD) is a progressive neurological disorder that results from degeneration of neurons in a region of the brain that controls movement, impacting an estimated 6.3 million people worldwide. To date, mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common genetic cause of PD. This poster describes biochemical and cellular assay formats to exploit the new reagents available. Together these technologies will advance the field of PD research and therapeutics by addressing the currently unmet need for modular over expression, inhibitor binding assays and cellular kinase assays for full-length LRRK2.